Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVTX-803 in Leukocyte Adhesion Deficiency Type II (LAD II)
NCT05462587Phase 3Recruiting
- Sponsor
- AUG Therapeutics
- Start
- Jul 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AUG-803 in leukocyte adhesion deficiency type II, sponsored by AUG Therapeutics. Started Jul 2022; status: recruiting.
02
Drugs
AUG-803
03
Conditions
leukocyte adhesion deficiency type II
Beyond the preview
Go deeper on NCT05462587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462587.